Network Pharmacology-Based Mechanistic Insights into SFI-Mediated Glioma Suppression

Study Background and Research Question

Gliomas represent the most common and aggressive form of primary brain tumors, with poor prognosis and limited treatment options despite advances in surgery, radiotherapy, and chemotherapy. Median survival remains under 17 months for most patients, underscoring the urgent need for novel therapeutic strategies. Traditional Chinese medicines, including the clinical adjuvant Shenqi Fuzheng injection (SFI), have shown promise in modulating tumor progression, yet their molecular mechanisms in glioma remain largely uncharacterized. The reference study (Li et al., 2024) specifically investigates the mechanistic underpinnings of SFI’s effects on glioma cell proliferation and migration using a network pharmacology approach.

Key Innovation from the Reference Study

The core innovation of the study lies in integrating network pharmacology with experimental validation to map the anti-glioma actions of SFI. By systematically identifying shared molecular targets between SFI components and glioma pathophysiology, the authors reveal that the SRC/PI3K/AKT signaling axis is central to SFI’s anti-tumor effects. This approach not only elucidates the multi-component, multi-target interactions typical of complex herbal formulations but also provides a blueprint for rationalizing traditional remedies in the context of modern molecular oncology.

Methods and Experimental Design Insights

The work combines computational and experimental methodologies. First, network pharmacology was employed to identify 26 major active components in SFI—derived from Codonopsis pilosula and Astragalus membranaceus—and their putative protein targets. The researchers cross-referenced these with 3,343 glioma-related targets from public databases, finding 79 overlapping molecules potentially mediating SFI's effects.

Experimental validation was performed using human glioma cell lines U87 and T98G, and a murine GL261 glioma model. Key assays included:

• CCK-8 and EdU proliferation assays
• Plate colony formation
• Scratch and Transwell migration assays
• Immunofluorescence and flow cytometry for cell cycle analysis
• Western blot for pathway and EMT marker assessment
• HE staining and immunohistochemistry in in vivo tumor tissues

This multi-tiered approach allowed for robust correlation between predicted molecular targets and observed phenotypic effects.

Core Findings and Why They Matter

Key findings from the study include:

• Inhibition of proliferation and migration: SFI significantly suppressed growth and motility of U87 and T98G glioma cells, with evidence of S-phase cell cycle arrest.
• Modulation of EMT markers: Reduced expression of proteins associated with epithelial-mesenchymal transition (EMT), indicating impaired invasive potential.
• In vivo tumor growth reduction: SFI treatment dramatically decreased tumor volume in a GL261 mouse model, substantiating the in vitro results.
• SRC/PI3K/AKT pathway involvement: Network and experimental data converge to show that SFI acts, at least in part, by blocking the SRC/PI3K/AKT signaling cascade—a critical regulator of both proliferation and migration in glioma cells.

These results suggest that multi-target agents like SFI can disrupt key oncogenic nodes, such as the SRC/PI3K/AKT pathway, with downstream effects on tumor progression. This aligns with previous evidence that anti-angiogenic and anti-migratory strategies, including those targeting VEGF and related kinases, may offer therapeutic benefit in aggressive brain tumors.

Comparison with Existing Internal Articles

APExBIO’s AAL-993 is a small-molecule VEGF receptor inhibitor frequently used in tumor angiogenesis research. According to internal resources (AAL-993: VEGF Receptor Inhibitor for Tumor Angiogenesis Research), AAL-993 exhibits nanomolar potency against VEGFR-2 and VEGFR-3, enabling precise anti-angiogenic modeling. The current SFI study complements this by highlighting a broader, network-based approach—where the anti-tumor effect is achieved not solely through VEGF signaling inhibition, but also through modulation of the SRC/PI3K/AKT axis. Internal articles such as AAL-993 in Tumor Angiogenesis: Mechanistic Insights & Translational Impact further discuss how targeted inhibitors facilitate mechanistic dissection in oncology, supporting the utility of both multi- and single-target strategies in experimental tumor models.

While AAL-993 enables high-specificity VEGF pathway interrogation, the SFI study illustrates the value of holistic approaches for complex diseases like glioma, especially when multiple oncogenic and microenvironmental processes are involved.

Limitations and Transferability

Despite the robust integration of computational and experimental methods, several limitations merit attention. The multi-component nature of SFI complicates the attribution of specific biological effects to individual compounds, and off-target actions cannot be fully ruled out. Additionally, while in vitro and murine models provide insight into mechanism, clinical efficacy in human glioma remains to be established. Transferability to other tumor types or to human application should be approached cautiously, as pathway dependencies and microenvironmental factors may differ.

The study’s focus on the SRC/PI3K/AKT pathway also suggests potential synergy with other pathway inhibitors, such as VEGF receptor antagonists, but direct combinatorial testing would be necessary to validate such strategies.

Protocol Parameters

• Network pharmacology screening: 26 SFI components mapped to 110 putative targets, with 79 shared with glioma tissue.
• Cell line assays: U87 and T98G cells treated with SFI at concentrations determined by CCK-8 viability curves; S-phase arrest assessed via flow cytometry after 24–48 hours.
• Migration assays: Scratch and Transwell migration evaluated after 24 hours of SFI exposure.
• In vivo model: GL261 cells injected subcutaneously into C57BL/6 mice; SFI administered per protocol and tumor volume assessed over 2–3 weeks.
• Pathway analysis: Western blot for SRC, PI3K, AKT phosphorylation states following SFI treatment (typically 24-hour exposure).

Research Support Resources

Researchers aiming to dissect angiogenic and anti-tumor mechanisms in glioma or related tumor models can supplement network pharmacology strategies with selective inhibitors. For example, AAL-993 (SKU C3730) from APExBIO is an established VEGF receptor inhibitor with high selectivity for VEGFR-2 and VEGFR-3, suitable for in vitro and in vivo angiogenesis assays. Its use can complement multi-target approaches by providing pathway-specific validation, especially where VEGF signaling intersects with the SRC/PI3K/AKT axis. As always, AAL-993 is intended for research use only, and protocols should be tailored to specific experimental requirements.